Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Stemgent Strike Distribution Pact

NEW YORK (GenomeWeb News) – Sigma-Aldrich said Tuesday that it will distribute Stemgent’s lentiviral vector-based technologies to the stem cell research community through a global agreement.

The worldwide distribution agreement covers Stemgent’s lentivirus-based delivery systems for induced pluripotent stem cells.

It includes Stemgent’s viral vectors, Sigma-Aldrich’s lentivirus technology, and Dox Inducible expression from Heidelberg, Germany-based TET Systems.

Stemgent’s technologies are aimed at researchers who are reprogramming mouse and human cells into iPS cells, particularly for use in regenerative medicine and disease studies.

Stemgent’s reagents and tools include small molecules for pluripotency, self-renewal, differentiation, viral-delivered transcription factors, cell lines, cytokines, transfection reagents, and others.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.